The Omicron Variant and the New Antivirals: How Much Will These Change the Pandemic in 2022?


In this UCSF Medicine Covid Grand Rounds, we’ll speak to two Covid experts – our own Dr. Annie Luetkemeyer and Prof. John Moore of the Weill Cornell Medical College.

Dr. Luetkemeyer will help us navigate the emerging world of the new oral antivirals for Covid-19 – how they work, what are good use cases, when to use monoclonal antibodies versus the new antivirals, the potential role of fluvoxamine, and how we might integrate these therapies into our Covid-19 arsenal.

Next, Prof. John Moore, an internationally known expert on microbiology and immunology, will help us distinguish hype from fact regarding the new Omicron variant in terms of its impact on transmission, immune escape, and severity – and what its emergence is likely to mean for the future course of the pandemic.

Note: Closed captions will be available within 48-72 hours after posting.

Program Bob Wachter: Introduction

00:04:1200:27:58 – Annie Luetkemeyer (UCSF Professor of Medicine in the Division of HIV, ID and Global Medicine at ZSFG)

00:27:5901:01:36 – John Moore (Professor of Microbiology and Immunology at the Weill Cornell Medical College) Bob Wachter: Closing

See previous Medical Grand Rounds:

• November 18: In Conversation with Mark Laret

• November 4: Covid-19 — Update on Vaccines and The State of the Pandemic with Paul Offit and George Rutherford

• October 28: Clinical Problem Solving

• October 14: Covid-19 — Lessons Learned and What’s Ahead: A Conversation with Ashish Jha

See all UCSF Covid-19 grand rounds, which have been viewed over 3M times, here:…